Ixaka
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
45 Pont St, London, Greater London, SW1X...Website
www.ixaka.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ixaka
Ixaka is a cell and gene therapy company focused on using the natural powers of the body to cure disease. Ixaka's proprietary technologies enhance the naturally therapeutic power of cells by increasing the presence of curative cells at the site of disease, or by directly modifying cells within the body to improve disease targeting and boost their restorative effect. Ixaka's technologies - concentrated multi-cell therapies and nanoparticle therapeutics - demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders. Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany.Explore more
Popular SearchesIxakaIxaka LtdSIC Code 28,283NAICS Code 32,325Show moreIxaka Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ixaka your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Ixaka
Ixaka, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Ixaka launches new products
Website visits: Recent activity has been detected on your website
Check out if Ixaka is spiking on competitors!
Click to see if Ixaka had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Ixaka has new funding data
Earning: See what the market has to say on Ixaka recently announced quarterly report
Check if Ixaka has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Ixaka
Compare insights from companies similar to Ixaka, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ixaka is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ixaka is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ixaka.
Ixaka Tech Stack
A closer look at the technologies used by Ixaka
Most Recent Scoops
New Hire
Executive Move
Ixaka has announced that Karen Miller has joined the company as Chief Scientific Officer. Previously, Miller was Senior VP, Pipeline Research for Adaptimmune PLC.
New Hire
Executive Move
Left Company
Executive Move
New Hire
Executive Move
Ixaka News & Media
Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle in vivo Gene Delivery Technology With Any Cargo in Any Therapeutic Area
LONDON--(BUSINESS WIRE)--Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its IP portfolio to allow a broad range of applications for its polymeric targeted nanoparticle (TNP) gene delivery platform across multiple therapeutic areas. The extended IP enables the development of therapies encapsulating any cargo including mRNA, plasmids and adenovirus associated virus (AAV), and gene editing technologies as well as lentiviral vector-based therapies. Ixaka’s TCELTIC-19 Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency
LONDON--(BUSINESS WIRE)--Ixaka Ltd announces ATMP classification has been granted by the EMA for its CELTIC-19 targeted nanoparticle product.Ixaka Expands Management Team with Multiple Appointments
LONDON--(BUSINESS WIRE)--Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, today announces the appointment of Nick Robbins-Cherry as Chief Financial Officer and board Director, and George O’Rourke as Vice President and General Manager of Ixaka France. Nick Robbins-Cherry joins Ixaka with 30 years of experience in fund-raising, public markets and PE gained through finance and commercial roles in international pharmaceuticals, technolIxaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001
LONDON--(BUSINESS WIRE)--Ixaka Ltd, an integrated cell and gene therapy company, announces positive interim results of its lead REX-001 drug candidate from a Phase 3 clinical trial, which evaluated the safety and efficacy results 12 months after treatment with REX-001 or placebo in patients diagnosed with chronic limb-threatening ischemia (CLTI) and diabetes. Following assessment of the interim efficacy and safety data, the independent Data Monitoring Committee (DMC) recommended continuation of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ixaka
Sign Up For FreeTo access detailed company insights
Ixaka is a cell and gene therapy company focused on using the natural powers of the body to cure disease. Ixaka's proprietary technologies enhance the naturally therapeutic power of cells by increasing the presence of curative cells at the site of disease, or by directly modifying cells within the body to improve disease targeting and boost their r... Read More
